Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in the Hong Kong with limited liability)

(Stock Code: 648)

PROFIT WARNING

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that the Group's loss for the six months ended 30 June 2016 is expected to increase substantially as compared to the six months ended 30 June 2015.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

This announcement is made by the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO").

The board (the "Board") of directors of China Wah Yan Healthcare Limited (the "Company", together with its subsidiaries, the "Group") wishes to inform the shareholders and potential investors of the Company that based on the preliminary assessment by the Board of the latest available unaudited consolidated management accounts of the Group, the Group's loss for the six months ended 30 June 2016 is expected to increase substantially as compared to the Group's loss of HK$24 million for the six months ended 30 June 2015 mainly due to, among others, the decrease in the fair value of approximately HK$180 million of the Group's financial and capital assets which are held for long-term investment purpose by the Group.

The Group is still in the process of preparing and finalising its unaudited consolidated results for the six months ended 30 June 2016, which is expected to be published on or before 31 August 2016 in accordance with the Listing Rules. The information contained in this announcement is only based on the Board's preliminary assessment of the latest available unaudited consolidated management accounts of the Group as at the date of this announcement, which have not been reviewed nor audited by the Company's auditors and are subject to adjustments. As such, the shareholders and potential investors of the Company are advised to read carefully the results announcement of the Company for the six months ended 30 June 2016 when it is published.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board of
China Wah Yan Healthcare Limited
Chan Ka Chung
Chairman

Hong Kong, 12 July 2016

As at the date of this announcement, the Board comprises three executive directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and four independent non-executive directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Dr. Tong Cheuk Man.